Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia

Inclusion Criteria: 1. Male or Female adult patients ≥18 years of age at the time of data collection. 2. Patient with a confirmed diagnosis of active moderate to severe HS. 3. Secukinumab naive patients (first dose to coincide within one month of the signature of the informed consent) as per locally approved label. 4. Patients can be using antibiotics or have undergone surgery as per routine clinical practice. 5. Patients agree to sign an informed consent form (ICF) to be able to complete the questionnaires. Exclusion Criteria: 1. Patients not fulfilling any of the above-mentioned inclusion criteria. 2. Patient's refusal to be included in the study or refusal to sign the ICF. 3. A history of off-label indication uses of biological treatment or JAK inhibitor.